United Therapeutics Corp. (UTHR)
593.31
-2.35
(-0.39%)
USD |
NASDAQ |
Nov 12, 16:00
593.38
+0.07
(+0.01%)
Pre-Market: 20:00
United Therapeutics Max Drawdown (5Y) : 33.00% for Oct. 31, 2026
Max Drawdown (5Y) Chart
Historical Max Drawdown (5Y) Data
| Date | Value |
|---|---|
| October 31, 2026 | 33.00% |
| September 30, 2026 | 33.00% |
| August 31, 2026 | 33.00% |
| July 31, 2026 | 33.00% |
| June 30, 2026 | 33.00% |
| May 31, 2026 | 33.00% |
| April 30, 2026 | 33.00% |
| March 31, 2026 | 33.00% |
| February 28, 2026 | 33.00% |
| January 31, 2026 | 33.00% |
| December 31, 2025 | 33.00% |
| November 30, 2025 | 33.00% |
| October 31, 2025 | 33.00% |
| September 30, 2025 | 39.51% |
| August 31, 2025 | 40.68% |
| July 31, 2025 | 40.68% |
| June 30, 2025 | 40.68% |
| May 31, 2025 | 40.68% |
| April 30, 2025 | 40.79% |
| March 31, 2025 | 50.82% |
| February 28, 2025 | 57.90% |
| January 31, 2025 | 57.90% |
| December 31, 2024 | 57.90% |
| November 30, 2024 | 57.90% |
| October 31, 2024 | 57.90% |
| Date | Value |
|---|---|
| September 30, 2024 | 58.47% |
| August 31, 2024 | 58.47% |
| July 31, 2024 | 58.47% |
| June 30, 2024 | 60.30% |
| May 31, 2024 | 60.30% |
| April 30, 2024 | 60.30% |
| March 31, 2024 | 60.30% |
| February 29, 2024 | 60.30% |
| January 31, 2024 | 60.30% |
| December 31, 2023 | 60.30% |
| November 30, 2023 | 60.30% |
| October 31, 2023 | 60.30% |
| September 30, 2023 | 60.30% |
| August 31, 2023 | 60.30% |
| July 31, 2023 | 60.30% |
| June 30, 2023 | 60.30% |
| May 31, 2023 | 60.30% |
| April 30, 2023 | 60.30% |
| March 31, 2023 | 60.30% |
| February 28, 2023 | 60.30% |
| January 31, 2023 | 60.30% |
| December 31, 2022 | 60.30% |
| November 30, 2022 | 60.30% |
| October 31, 2022 | 60.30% |
| September 30, 2022 | 60.30% |
Max Drawdown Definition
Max drawdown is an indicator of the risk of a portfolio chosen based on a certain strategy. It measures the largest single drop from peak to bottom in the value of a portfolio before a new peak is achieved.
Max Drawdown (5Y) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Max Drawdown (5Y) Benchmarks
| Liquidia Corp. | 90.94% |
| Alnylam Pharmaceuticals, Inc. | 66.41% |
| Exelixis, Inc. | 53.09% |
| Gilead Sciences, Inc. | 26.58% |
| Insmed, Inc. | 63.30% |
Max Drawdown (5Y) Related Metrics
| Alpha (5Y) | 17.86 |
| Beta (5Y) | 0.4855 |
| Annualized Standard Deviation of Monthly Returns (5Y Lookback) | 31.94% |
| Historical Sharpe Ratio (5Y) | 0.684 |
| Historical Sortino (5Y) | 1.700 |
| Monthly Value at Risk (VaR) 5% (5Y Lookback) | 10.10% |